Cassava Sciences GAAP EPS of -$0.26
Cassava Sciences press release (FLNA): Q4 GAAP EPS of -$0.26. Net cash used in operations was $32.3 million in 2025,...
Tag: SAVA
Cassava Sciences to rebrand to Filana Therapeutics
Cassava Sciences (SAVA) said it will change its name to Filana Therapeutics, reflecting its focus on developing drugs that...
Cassava says DoJ has ended probe into research misconduct
Cassava Sciences (SAVA) announced on Thursday that the Fraud Section of the U.S. Department of Justice has closed an...
Cassava Sciences to pay $31.25M to settle securities class action suit
Cassava Sciences (SAVA) announced on Tuesday that it agreed to pay $31.25M to settle a class action lawsuit pending in a...
Cassava Sciences drops on delay for epilepsy study
Cassava Sciences (SAVA) fell ~14% in the premarket on Friday after the company said it will be forced to delay a clinical...
Cassava Sciences hit with FDA request for more data on simufilam trial
Cassava Sciences (SAVA) said in a filing the FDA has asked for more information before allowing its investigational new...
Cassava Sciences rises 10% after market close on CEO stock buy
Cassava Sciences has popped 10% in after-market-close trading Monday following an SEC filing indicated that CEO Richard...
Cassava Sciences spikes as CEO buys stock
Shares of Cassava Sciences (SAVA) added ~5% in the premarket on Friday after Richard Barry, President and Chief Executive...
Cassava Sciences files $200M mixed securities shelf
Cassava Sciences (SAVA) has filed a shelf registration statement with the SEC to offer up to $200 million worth of mixed...
Cassava says court dismisses criminal case against scientist
Cassava Sciences (NASDAQ:SAVA) shares rose as much as 6% premarket on Friday after a U.S. court dismissed a criminal case...